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Abstract
Background: Little is known about racial and ethnic differences in individuals with sporadic Creutzfeldt-Jakob disease
(sCJD). The authors sought to examine potential clinical, diagnostic, genetic, and neuropathological differences in sCJD
patients of different races/ethnicities.
Methodology/Principal Findings: A retrospective study of 116 definite and probable sCJD cases from Johns Hopkins and
the Department of Veterans Affairs Healthcare Systems was conducted that examined differences in demographic, clinical,
diagnostic, genetic, and neuropathological characteristics among racial/ethnic groups. Age at disease onset differed among
racial/ethnic groups. Non-Hispanic Whites had a significantly older age at disease onset compared to the other groups (65
vs. 60, p=0.036). Non-Whites were accurately diagnosed more rapidly than Whites (p=0.008) and non-Hispanic Whites
were more likely to have normal appearing basal ganglia on brain magnetic resonance imaging (MRI) compared to
minorities (p=0.02). Whites were also more likely to undergo post-mortem evaluation compared to non-Whites (p=0.02).
Conclusions/Significance: Racial/ethnic groups affected by sCJD demonstrated differences in age at disease onset, time to
correct diagnosis, clinical presentation, and diagnostic test results. Whites were more likely to undergo autopsy compared
to non-Whites. These results have implications in regards to case ascertainment, diagnosis, and surveillance of sCJD and
possibly other human prion diseases.
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Introduction
Creutzfeldt-Jakob disease (CJD) is a rapidly progressive, fatal,
neurodegenerative disease caused by a pathologic and trans-
missible form of the native prion protein (PrP
Sc) [1]. Sporadic
Creutzfeldt-Jakob disease (sCJD) is the most common form of
human prion disease with a worldwide incidence ranging from 0.4
to 2.63 individuals per million people per year [2–6]. sCJD often
presents with neurological symptoms such as dementia, gait
disturbance, myoclonus, visual changes, and motor impairments
[7]. Prior epidemiological studies of sCJD in the United States of
America (U.S.A) have reported a lower age adjusted incidence rate
for Blacks compared to Whites, the reasons for which are
unknown [8].
The goal of this study was to further explore demographic and
diagnostic differences among race/ethnicity of patients with sCJD.
The findings of this study emphasize the importance of including
race and ethnicity data in future surveillance and research efforts
of human prion diseases.
Methods
Objectives
To further investigate demographic and diagnostic differences
among races and ethnicities of patients with sCJD.
Participants
Previously collected data between 1995–2010 from Johns
Hopkins (JH) and the Department of Veterans Affairs Health
Care System (VHS) were analyzed [9]. Using a standardized
collection instrument, clinical data were abstracted from medical
records of subjects by two of the authors (BSA and KKA) who
have clinical and research experience with human prion diseases
(Protocol S1). At least twelve of the subjects had been personally
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JH is a tertiary medical center that receives many national
referrals. The VHS is the largest integrated healthcare system
within the U.S.A. and services all of the U.S.A. and occupied
territories while providing healthcare to approximately 30% of
the veterans’ population [10]. Although the sex ratio is biased
towards men (approximately 85% of the population), the racial
and ethnic diversity of the VHS reflects that seen in the general
population of the U.S.A. [11,12]. As such, VHS data have been
used to assess the incidence and risk factors of other
neurological disorders among different races/ethnicities [13].
Hence the sample population is geographically heterogeneous
and derived from both general and specialized medical centers.
Only probable and definite cases of sCJD were included in the
final analyses. Definite sCJD was determined using previously
established criteria [14]. Clinically probable sCJD was determined
using recent criteria that include brain magnetic resonance
imaging (MRI) data [15]. Only MRI data with diffusion weighted
(DWI) and fluid attenuated inversion recovery (FLAIR) sequences
were used. When available, MRI images were reviewed by
experienced prion disease clinicians and researchers (BSA and
KKA). In a minority of cases images were not available and
neuroradiology reports were used. Racial and ethnic groups were
defined by current U.S.A. Census categories [16] and included
non-Hispanic Whites, White Hispanics, and non-Hispanic Blacks
or African- Americans. Subjects that were not included in these
groups were categorized as ‘‘other.’’
Description of Procedures or Investigations Undertaken
Medical records of the aforementioned subjects were reviewed
using a standardized abstraction instrument by two investigators
(B.S.A. and K.K.A.) (Protocol S1). Information on age and date
at disease onset, defined as the time at which the first persistent
and progressive symptom occurred during the subject’s course
of illness, dates at the time of initial presentation to a healthcare
professional, diagnosis of CJD, and date of death were collected.
Symptoms and their dates at onset were collected. Cerebrospi-
nal fluid (CSF) 14-3-3 protein, electroencephalogram (EEG),
and brain MRI results in addition to neuropathological and
genetic data were collected from the medical record or through
the assistance of the National Prion Disease Pathology
Surveillance Center (NPDPSC, www.cjdsurveillance.com).
Ethics
This study analyzed previously collected data from JH and the
VHS. Data was collected from 1995–2010 and were analyzed
following IRB approval from both centers as discussed in
a previously published paper [9].
Statistical Methods
Analyses of variance (ANOVA), t-tests, Mantel-Cox analyses,
and Cox proportional hazard models were used for continuous
variables and Chi-square analyses were used for categorical
variables. Logistic regression analyses were used to control for
possible confounding factors. Statistical significance was de-
termined by a p-value #0.05. IBM SPSS version 19 statistical
software was used for performing analyses.
Results
116 cases of sCJD were included in the present study. Table 1
lists demographic characteristics of study subjects. Racial and
ethnic breakdown within the ‘‘other’’ category included American
Indian, mixed race, Black Hispanic, and unspecified. Data did not
include Asian subjects as no Asian cases were ascertained in the
data collection process.
Age at disease onset differed between racial/ethnic groups
(Table 1). Although age at disease onset did not differ across all
groups in an ANOVA analysis (p=0.103), non-Hispanic Whites
had a significantly older mean age at onset compared to the other
groups (65 vs. 60 years) (t-test, t=–2.13, df=114, p=0.036).
Subjects in the ‘‘other’’ group had the youngest mean age at onset
(56 years, SD=7.0) followed by non-Hispanic Blacks (59 years,
SD=10.9) and Hispanic Whites (64 years, SD=9.2). Although the
‘‘other’’ group had a much shorter mean survival time (5 months,
SD=2.2), racial/ethnic groups did not differ significantly in
disease duration (p=0.68) (Table 1).
Time from disease onset to correct diagnosis differed signifi-
cantly between non-Hispanic and Hispanic Whites (197 days,
SD=174) and non-Whites (46.7 days, SD=33.7) (Mantel-Cox,
chi-square =7.1, p=0.008) (Figure 1). Although there was no
statistically significant difference between time from disease onset
to initial presentation to a healthcare professional, non-White
patients (n=3) were correctly diagnosed significantly earlier
(mean=46.7 days, SD=33.7) compared to non-Hispanic and
Hispanic Whites (n=24) (mean=197.3 days, SD=174.2) (Man-
tel-Cox, chi-square =7.1, p=0.008). Differences in mean time to
correct diagnosis remained between the two groups (p=0.03)
Table 1. Demographic characteristics of study subjects.
Characteristic Non-Hispanic Whites Non-Hispanic Blacks Hispanic Whites Other
a Total
(n=100, 86%) (n=6, 5%) (n=6, 5%) (n=4, 4%) (n=116, 100%)
Age, mean (SD), y 65 (9.3)
b 59 (10.9) 64 (9.2) 56 (7.0) 65 (9.4)
Survival time, mean (SD), mo 10.5 (15.4) 10.7 (7.4) 16.2 (22.1) 5 (2.2) 10.6 (15.2)
Center (%)
JH 71 (71) 5 (83) 0 (0) 3 (75) 79 (68)
VHS 29 (29) 1 (17) 6 (100) 1 (25) 37 (32)
Male (%) 65 (65) 4 (67) 6 (100) 3 (75) 78 (67)
Definite sCJD (%) 59 (59) 3 (50) 3 (50) 1 (25) 66 (57)
JH=Johns Hopkins, VHS=Veterans Administration Healthcare System, sCJD = sporadic Creutzfeldt-Jakob disease.
aIncludes American Indian, mixed race, Hispanic Black, and unspecified.
bp=0.036.
doi:10.1371/journal.pone.0038884.t001
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proportional hazards model.
The presence of different clinical symptoms did not differ
between racial/ethnic groups (Table 2), but time to onset of
specific symptoms did vary. Subjects in the ‘‘other’’ category
presented with movement disorder symptoms (n=3, 5 weeks,
SD=2.6) earlier than the other groups (n=70, 25.6 weeks,
SD=4) in cases when date of symptom onset was known (Mantel-
Cox, chi-square =4.7, p=0.03). The non-Hispanic Black (n=2,
11.5 weeks, SD=3.5) and ‘‘other’’ racial/ethnic groups (n=3,
3 weeks, SD=3) also presented with language impairments earlier
in their disease course compared to non-Hispanic Whites (n=41,
32.7 weeks, SD=49.3) (Mantel-Cox, chi-square=7.3, p=0.03) in
cases when date of symptom onset was known.
Ethnic groups also differed in their time from disease onset to
undergoing certain diagnostic tests (Table 3). Members of the
‘‘other’’ group had EEGs performed earlier than the other racial/
ethnic groups (p=0.046, HR=2.9, 95% CI=1.0–8.3). An initial
EEG was performed at a mean of 7.8 weeks (SD=5.3) after
disease onset in the ‘‘other’’ group compared to 27.1 weeks
(SD=35.7) in the remaining racial/ethnic groups. This finding
was no longer statistically significant when age at disease onset was
entered into the model (p=0.051).
Figure 1. Time to correct diagnosis of sporadic Creutzfeldt-Jakob disease subjects by race/ethnicity. White race includes non-Hispanic
and Hispanic Whites (Mantel-Cox, chi-square =7.1, p=0.008).
doi:10.1371/journal.pone.0038884.g001
Table 2. Clinical symptoms of subjects throughout the disease course.
Clinical Symptoms (%) Non-Hispanic Whites Non-Hispanic Blacks Hispanic Whites Other Total
(n=100) (n=6) (n=6) (n=4) (n=116)
Cognitive 94 (94) 6 (100) 6 (100) 4 (100) 110 (95)
Cerebellar 82 (82) 4 (67) 5 (83) 3 (75) 94 (81)
Movement disorder 66 (66) 2 (33) 4 (67) 3 (75) 75 (65)
Visual 65 (65) 3 (50) 3 (50) 3 (75) 74 (64)
Myoclonus 61 (61) 5 (83) 5 (83) 2 (50) 73 (63)
Mood 49 (49) 2 (33) 5 (83) 2 (50) 58 (50)
Psychosis 41 (41) 2 (33) 2 (33) 2 (50) 47 (41)
Motor 25 (25) 1 (17) 2 (33) 1 (25) 29 (25)
Cognitive: cognitive decline, executive dysfunction, amnesia, agnosia, apraxia, alexia, language impairment, disorientation, and/or concentration impairment;
Cerebellar: ataxia, nystagmus, and/or vertigo; Movement disorder: tremor, chorea, and/or extrapyramidal symptoms (does not include myoclonus); Visual: diplopia,
oculomotor palsy, hemianopia, cortical blindness, visuospatial impairment, and/or visual hallucinations; Mood: depression, anxiety, mania, hypomania, emotional
lability, and/or apathy; Psychosis: delusions, hallucinations, and/or psychosis not otherwise specified.
doi:10.1371/journal.pone.0038884.t002
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(Table 4). Non-Hispanic Whites (44/95, 46%) were less likely to
have hyperintensity of the basal ganglia on.
brain MRI compared to other races/ethnicities (12/15, 80%)
(Fisher’s exact test, 2-sided, p=0.024). This finding remained
significant in a binary logistic regression model that included age
at disease onset (p=0.023). There were no statistically significant
differences in the prevalence of vascular disease or vascular risk
factors (stroke, diabetes mellitus, hypertension, coronary artery
disease, or hyperlipidemia) between these two groups.
Although tissue confirmed diagnoses did not differ significantly
between groups, non-Hispanic Blacks and ‘‘other’’ racial/ethnic
groups were less likely to undergo autopsy (1/10, 10%) compared
to non-Hispanic and Hispanic Whites (51/103, 49.5%) (Fisher’s
exact test, 2- sided, p=0.02) (Table 5). JH (16/78, 21%) pursued
a more aggressive brain biopsy policy compared to the VHS (2/
35, 6%) (Fisher’s exact test, 2-sided, p=0.054). Full prion protein
gene (PRNP) analyses were performed on 45 cases (38.8%)
(Table 5). No pathogenic mutations or family history of prion
diseases were present in this sample. No statistically significant
differences were detected in the codon 129 polymorphism of
PRNP or prion protein type (I, II, I and II) between race/ethnic
groups (Table 5).
Discussion
Epidemiological studies are important in the field of human
prion diseases given the risk of acquired prion disease and
previously recognized genetic factors that affect susceptibility to
the disease [17,18]. Prior epidemiological studies within the U.S.
have demonstrated a lower age-adjusted incidence of prion disease
in Blacks [8] compared to Whites. Additionally, few cohorts are
available to evaluate the morbidity of prion disease in minorities
within the U.S.A.
In this study population, minority patients had an earlier age at
disease onset compared to non-Hispanic Whites. Non-White
patients received an accurate clinical diagnosis more quickly than
non-Hispanic and Hispanic Whites. While there was not
a statistically significant difference between the race/ethnic groups
with regard to disease duration, the ‘‘other’’ group had consid-
erably shorter illness duration (5 months) compared to the other
groups. Although this sample’s mean survival time (10.6 months)
was longer than what has been described in European studies (7.3
months) [19], it is consistent with prior U.S. studies (8.46–12.62
months) [20]. Moreover, a large European study examining
factors that affect survival time noted differences in this statistic
Table 3. Diagnostic testing data of study sample.
Diagnostic Test Results Non-Hispanic Whites Non-Hispanic Blacks Hispanic Whites Other Total
(n=100) (n=6) (n=6) (n=4) (n=116)
14-3-3 performed (%)
a 66 (66) 4 (67) 4 (67) 3 (75) 77 (66)
Mean time to 14-3-3 (s.e.), wks 18.6 (2.9) 18 (5.1) 75.5 (54) 6.3 (3.4) 21.4 (4.1)
+14-3-3 (%)
b 41/60 (68) 2/3 (67) 4/4 (100) 2/2 (100) 49/69 (71)
EEG performed (%)
c 89/96 (93) 6/6 (100) 4/6 (67) 4/4 (100) 103/112 (92)
Mean # of EEG’s performed 1.6 1.5 1.3 1 1.5
Mean time to EEG (s.e.), wks 28 (4.7) 30 (11) 73 (56) 7.8 (2.7) 30 (5)
PSWC (%)
a 30/89 (34) 3/6 (50) 1/4 (25) 2/4 (50) 36/103 (35)
EEG=electroencephalogram; PSWC = periodic sharp wave complexes.
aUnknown in 9 cases.
bUnknown in 8 cases.
cUnknown in 4 cases.
doi:10.1371/journal.pone.0038884.t003
Table 4. Brain magnetic resonance imaging (MRI) characteristics of study subjects.
Area of Hyperintensity Non-Hispanic Whites Non-Hispanic Blacks Hispanic Whites Other Total
(n=95) (n=5) (n=6) (n=4) (n=110)
Mean # of brain MRI’s (SD) 1.8 (0.75) 1.5 (1) 1.5 (0.54) 1.75 (0.5) 1.75 (0.74)
Median time from onset to initial MRI
(S.E), wks
a
10 (1.96) 13 (3.46) 17 (6.12) 5 (4.5) 11 (1.69)
Basal ganglia (%) 44 (46)
b 4 (80) 5 (83) 3 (75) 56 (51)
Thalamus (%)
c 15 (16) 1 (20) 1 (17) 2 (50) 19 (17)
Meets cortical criteria (%)
d 29 (31) 1 (20) 2 (33) 2 (50) 34 (31)
Meets Brain MRI Criteria for sCJD (%)
e 57 (60) 4 (80) 6 (100) 3 (75) 70 (64)
Brain MRI was not done for 2 subjects and results were unknown in 4 subjects.
aimes could not be calculated for 7 subjects.
bp,0.05.
c13/15 cases also had basal ganglia hyperintensity.
dHyperintensity on DWI/FLAIR in 2 or more cortical areas (temporal, parietal, or occipital lobes) [15].
eHigh signal abnormalities in caudate nucleus and putamen or at least two cortical regions (temporal-parietal-occipital) either in DWI or FLAIR [15].
doi:10.1371/journal.pone.0038884.t004
Racial/Ethnic Differences in sCJD
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e38884between countries [19] that may be influenced by the country’s
attitudes towards end of life care [21].
This discrepancy in time from disease onset to diagnosis might
be due, in part, to differences in the time of onset of specific
symptoms between the race/ethnic groups. Subjects in the ‘‘other’’
category presented with movement disorder symptoms earlier than
non-Hispanic White subjects. Perhaps the earlier presence of
movement disorder symptoms in these younger subjects aided in
making the correct diagnosis more apparent. Similarly, non-
Hispanic Black and ‘‘other’’ subjects had an earlier onset of
language impairment compared to non-Hispanic Whites. The
earlier manifestation of these symptoms may have enabled a more
timely diagnosis of sCJD in minorities by clinicians. Additionally,
access to medical care within the VHS, a centralized healthcare
system with a standardized electronic medical record, in contrast
to private healthcare systems or other government programs may
have improved detection of symptoms for minorities and/or
Hispanic Whites.
Racial/ethnic groups also differed in the time from disease onset
to undergoing certain diagnostic tests. Members of the ‘‘other’’
group had EEGs performed earlier than other races/ethnicities,
although this was partly influenced by the age of the patient in
addition to his or her race/ethnicity.
Initial brain MRI findings also differed between race/ethnic
groups. Non-Hispanic White patients were more likely to have
normal appearing basal ganglia compared to minority groups.
This group had a lower percentage of abnormal brain MRI’s than
what would be expected (60% vs. 81%), which may have biased
analyses [15]. As brain MRI findings enter into the diagnostic
criteria when diagnosing sCJD, a higher rate of abnormal findings
in this study’s minority patients may have aided physicians in
making a more timely diagnosis in these racial/ethnic groups.
Many prior studies have revealed genetic associations with
clinical characteristics of human prion disease. Age at disease
onset, survival time, and clinical and neuropathological pheno-
types are influenced by PRNP codon 129 polymorphism and
prion protein type [22,23]. The normal distribution of the codon
129 polymorphism varies throughout the world and across ethnic
groups [24]. Hence different ethnicities may differ in codon 129
polymorphisms, which could affect age at disease onset, clinical
manifestations, and diagnostic test results. Given the small
sample size of minorities in the current study, a larger sample
of different racial/ethnic groups with genetic and neuropatho-
logical data are needed to properly interpret the associations
found in this study.
While tissue diagnosis did not differ significantly between race/
ethnic groups, non-White subjects were less likely to undergo
autopsies. This finding is particularly important when considering
reported incidence rates of sCJD that rely heavily on autopsy-
derived data. The decreased autopsy rate in minorities could
significantly influence the reported incidence of sCJD in this
population and result in a falsely lower incidence rate. This is
further complicated by the declining autopsy rates in general over
the past 5 decades in the U.S.A., which are performed in fewer
than 6% of non-forensic deaths [25]. Education provided through
clinicians and advocacy groups regarding the importance of and
the resources available to perform autopsies on suspected cases of
sCJD are crucial to ameliorate the lower autopsy rate in non-
Whites. These findings also accentuate the importance of robust
clinical sCJD surveillance efforts.
Table 5. Neuropathologic and molecular data of study subjects.
Characteristic Non-Hispanic Whites Non-Hispanic Blacks Hispanic Whites Other Total
(n=100) (n=6) (n=6) (n=4) (n=116)
Tissue collected (%) 63 (63)
a 3 (50) 4 (67) 1 (25) 71 (61)
Autopsy (%)
b 47 (47) 1 (17) 4 (67) 0 52 (45)
Biopsy (%) 15 (15) 2 (33) 0 1 (25) 18 (16)
PRNP analysis performed (%) 39 (39) 2 (33) 3 (50) 1 (25) 45 (39)
PRNP codon 129 (%)
c MM=16 (42) MM=0 MM=1 (33) MM=1 (100) MM=18 (42)
MV=15 (40) MV=0 MV=2 (67) MV=0 MV=17 (40)
VV=7 (18) VV=1 (100) VV=0 VV=0 VV=19 (18)
Molecular subtype (%)
d
MM1 11 (30) 1 (33) 1 (100) 13 (31)
MM2 2 (5) 2 (5)
MM1&2 2 (5) 2 (5)
MV1 6 (16) 6 (14)
MV2 2 (5) 2 (67) 4 (10)
MV1&2 5 (14) 5 (12)
VV1 1 (3) 1 (2)
VV2 4 (11) 4 (10)
VV1&2 2 (5) 1 (100) 3 (7)
MVPSPr 2 (5) 2 (5)
PRNP=prion protein gene, M=methionine, V=valine, PSPr=protease sensitive proteinopathy.
aIt was unknown whether tissue was from an autopsy or biopsy in 3 cases.
bAny White race vs. any non-White race (Fisher’s exact test, 2-sided, p=0.02).
cWe could not confirm PRNP codon 129 genotype in 2 cases.
dDefined as PRNP codon 129 genotype and prion protein type(s).
doi:10.1371/journal.pone.0038884.t005
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various aspects of sCJD among different race/ethnic groups.
Demographic, clinical, and diagnostic differences were ascertained
as well as differences in autopsy rates. These findings accentuate
the importance of including race and ethnicity data in future
studies and surveillance efforts of human prion disease.
Limitations
Different ethnicities may differ in codon 129 polymorphism
which could affect age at disease onset, disease duration, clinical
manifestations, and diagnostic test results. Given the small sample
size of minorities in the current study, a larger sample of different
racial/ethnic groups with genetic and neuropathological data is
needed to properly interpret the associations found in this study.
Also, because non-White subjects are less likely to undergo
autopsies, the decreased autopsy rate in minorities could
significantly influence the reported incidence of sCJD in this
population and result in a falsely lower incidence rate. All MRI
images were not available for standardized analyses and this may
have affected these data. No Asians were included in this study and
the previously reported low incidence rate of sCJD in Taiwan and
Japan (0.63–1.1 individuals per million people) make them an
important sample to include in future studies [3,4]. A prospective
study capturing clinically diagnosed and neuropathologically
confirmed cases of sCJD would be an ideal study that would
maximize reliability.
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